Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.46 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.46 |
| ▸ | SLC34A1 | Q06495 | 12/20 | 0.37 |
| ▸ | IDH1 | O75874 | 4/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31127312 | 1.00 | KCNN2 (0.46) | KCNN2KCNN3SLC34A1IDH1IRAK4 | |
| SCHEMBL21166179 | 0.89 | KCNN2 (0.42) | KCNN2KCNN3SLC34A1IDH1TSHR | |
| SCHEMBL31127324 | 0.89 | KCNN2 (0.42) | KCNN2KCNN3SLC34A1IDH1TSHR | |
| SCHEMBL19686284 | 0.86 | KCNN2 (0.49) | KCNN2KCNN3IDH1TSHRSMN1; SMN2 | |
| SCHEMBL19687524 | 0.86 | KCNN2 (0.40) | KCNN2KCNN3SLC34A1 | |
| SCHEMBL19686887 | 0.85 | KCNN2 (0.48) | KCNN2KCNN3IDH1TSHRSMN1; SMN2 | |
| SCHEMBL19686300 | 0.85 | KCNN2 (0.46) | KCNN2KCNN3SLC34A1IDH1TSHR | |
| SCHEMBL19686732 | 0.84 | KCNN3 (0.47) | KCNN2KCNN3SLC34A1IDH1TSHR | |
| SCHEMBL19686445 | 0.84 | PRKD1 (0.37) | IDH1IRAK4 | |
| SCHEMBL21144126 | 0.84 | KCNN2 (0.45) | KCNN2KCNN3SLC34A1IDH1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| WO-2017139697-A9 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | KCNN2 5/4885KCNN3 11/4885SLC34A1 195/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | KCNN2 5/4885KCNN3 11/4885SLC34A1 195/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | KCNN2 5/4885KCNN3 11/4885SLC34A1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.